- Home
- PIII vs SLGL Comparison
PIII vs SLGL Comparison
Compare PIII & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | SLGL |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 117.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | PIII | SLGL |
|---|---|---|
| Price | $4.21 | $42.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $16.25 | ★ $50.00 |
| AVG Volume (30 Days) | 10.7K | ★ 14.2K |
| Earning Date | 11-13-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,444,952,000.00 | $18,970,000.00 |
| Revenue This Year | N/A | $121.82 |
| Revenue Next Year | $12.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $4.01 | $4.02 |
| 52 Week High | $14.50 | $52.26 |
Technical Indicators
Market Signals| Indicator | PIII | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 21.04 | 55.90 |
| Support Level | $5.01 | $39.26 |
| Resistance Level | $5.20 | $44.04 |
| Average True Range (ATR) | 0.22 | 3.07 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 2.48 | 66.20 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.